Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
出版年份 2021 全文链接
标题
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
作者
关键词
-
出版物
Future Oncology
Volume 17, Issue 7, Pages 755-757
出版商
Future Medicine Ltd
发表日期
2021-01-29
DOI
10.2217/fon-2020-0986
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
- (2020) L.-T. Chen et al. ANNALS OF ONCOLOGY
- CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
- (2020) Stephen P Hack et al. Future Oncology
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
- (2020) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
- (2020) Robin Kate Kelley et al. Future Oncology
- Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing
- (2020) Alessandro Rizzo et al. Future Oncology
- Optimizing Survival by Changing the Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review
- (2020) Howard Lim et al. JNCI-Journal of the National Cancer Institute
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now